Who Exports Carboplatin from India — 273 Suppliers Behind a $70.9M Market
India's carboplatin export market is supplied by 273 active exporters who collectively shipped $70.9M across 3,637 shipments. FRESENIUS KABI ONCOLOGY LIMITED leads with a 38.8% market share, followed by EUGIA PHARMA SPECIALITIES LIMITED and INTAS PHARMACEUTICALS LIMITED. The top 5 suppliers together control 65.8% of total export value, reflecting a concentrated market structure.
Top Carboplatin Exporters from India — Ranked by Export Value
FRESENIUS KABI ONCOLOGY LIMITED is the leading carboplatin exporter from India, holding a 38.8% share of the $70.9M market across 3,637 shipments from 273 exporters. The top 5 suppliers — FRESENIUS KABI ONCOLOGY LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, INTAS PHARMACEUTICALS LIMITED, GLAND PHARMA LIMITED, NV REMEDIES PRIVATE LIMITED — collectively control 65.8% of total export value, indicating a moderately concentrated market. Individual shares are: FRESENIUS KABI ONCOLOGY LIMITED (38.8%), EUGIA PHARMA SPECIALITIES LIMITED (9.9%), INTAS PHARMACEUTICALS LIMITED (6.8%), GLAND PHARMA LIMITED (6.0%), NV REMEDIES PRIVATE LIMITED (4.1%).
Top Carboplatin Exporters from India
Ranked by export value · 273 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | FRESENIUS KABI ONCOLOGY LIMITED KEMOCARB BP INJ. 450MG/45MKEMOCARB BP INJ. 450MG/45ML VIALCARBOPLATIN FRESENIUS KABI INJ. 450MG/45 | $27.5M | 29 | 38.8% |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED CARBOPLATIN INJECTION 600MG/60MLCARBOPLATIN INJECTION 450MG/45MLCARBOPLATIN INJECTION 10 MG/ML - US )NOS | $7.0M | 3 | 9.9% |
| 3 | INTAS PHARMACEUTICALS LIMITED NAPROPLAT 450MG/45ML CARBOPLATIN INJECTKEMOCARB INJ. BP 450MG/45ML, | $4.9M | 20 | 6.8% |
| 4 | GLAND PHARMA LIMITED CARBOPLATIN INJECTION 600MG/60MLCARBOPLATIN INJECTION 450MG/45MLCARBOPLATIN INJECTION 10 MG/ML - US )NOS | $4.3M | 1 | 6.0% |
| 5 | NV REMEDIES PRIVATE LIMITED | $2.9M | 2 | 4.1% |
| 6 | VENUS REMEDIES LIMITED CARBOPLATIN FRESENIUS KABI INJ. 450MG/45CARBOPLATIN KABI INJ. 600MG/60ML VIAL (ICARBOPLATIN KABI INJ. 450MG/45ML VIAL(IT | $2.7M | 22 | 3.8% |
| 7 | KARDI TRADING PRIVATE LIMITED KEMOCARB BP INJ. 450MG/45MKEMOCARB BP INJ. 450MG/45ML VIAL | $2.6M | 8 | 3.7% |
| 8 | NAPROD LIFE SCIENCES PRIVATE LIMITED KEMOCARB BP INJ. 450MG/45MKEMOCARB BP INJ. 450MG/45ML VIALNAPROPLAT 450MG/45ML CARBOPLATIN INJECT | $2.6M | 11 | 3.7% |
| 9 | ACCURE LABS PRIVATE LIMITED ACUCARB 150ACUCARB 450ACUCARB 450 PRIVATE CARBOPLATIN INJECTION BP 450 MG 45ML | $1.5M | 1 | 2.1% |
| 10 | BETA DRUGS LIMITED | $1.1M | 16 | 1.6% |
| 11 | PLEASANT EXPORTS CARBOPLATIN 450 INJCARBOPLATIN INJECTION BP 10MG/ML /VIALCARBOPLATIN 150 INJ | $1.1M | 1 | 1.5% |
| 12 | INTAS PHARMACEUTICALS LTD NAPROPLAT 450MG/45ML CARBOPLATIN INJECTKEMOCARB INJ. BP 450MG/45ML, | $978.6K | 6 | 1.4% |
| 13 | TEYRO LABS PRIVATE LIMITED CARBOPLATIN INJECTION 600MG/60MLCARBOPLATIN INJECTION 450MG/45MLCARBOPLATIN INJECTION 10 MG/ML - US )NOS | $934.6K | 1 | 1.3% |
| 14 | CELON LABORATORIES PRIVATE LIMITED CARBOPLATIN 450 INJNAPROPLAT 450MG/45ML CARBOPLATIN INJECTKEMOCARB INJ. BP 450MG/45ML, | $628.5K | 11 | 0.9% |
| 15 | JODAS EXPOIM PRIVATE LIMITED CARBOPLATIN 450 INJCARBOPLATIN INJECTION BP 10MG/ML /VIALCARBOPLATIN 150 INJ | $475.9K | 1 | 0.7% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Carboplatin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Fresenius Kabi Oncology Limited | Warning Letter (December | Yes (Certified as of | Yes | Not verified | Received FDA warning letter for CGMP violations; holds WHO-GMP and EU GMP certif |
| Eugia Pharma Specialities Limited | Approved | Yes (Certified as of | Unknown | 179 | Received FDA approval for Pazopanib Tablets; holds WHO-GMP certification. |
| Intas Pharmaceuticals Limited | Approved | Yes (Certified as of | Yes | Not verified | First Indian company to receive EU GMP certification in April 2007; holds WHO-GM |
| Celon Laboratories Private Limited | Unknown | Yes (Certified as of | Unknown | Not verified | Holds WHO-GMP certification as of November 2025. |
| Jodas Expoim Private Limited | Unknown | Yes (Certified as of | Unknown | Not verified | Holds WHO-GMP certification as of November 2025. |
TransData Nexus reviewed the regulatory standing of 5 leading Carboplatin exporters from India. 2 hold US FDA facility approvals, 5 maintain WHO-GMP certification, and 2 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Carboplatin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for pharmaceutical manufacturing, particularly in active pharmaceutical ingredients (APIs). Eugia Pharma Specialities Limited, a subsidiary of Aurobindo Pharma, is headquartered here. Established in 2013, Eugia specializes in general injectables and oncology products, operating globally with facilities and teams in the USA, Europe, Brazil, Mexico, Canada, Colombia, ANZ, and select RoW markets. The company employs over 150 scientists and 4,000 staff worldwide, focusing on complex injectables and advanced R&D in Hyderabad, particularly in developing peptides, long-acting injectables, and sophisticated ophthalmic and dry powder injections.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations, housing major companies like Intas Pharmaceuticals Limited. Intas is a key player in the production of Carboplatin formulations, contributing significantly to India's export figures. The region's robust infrastructure and skilled workforce make it a strategic location for pharmaceutical manufacturing and export.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products, leveraging its proximity to major ports and international shipping routes. Companies like Gland Pharma Limited operate in this region, facilitating efficient distribution of Carboplatin to global markets. The area's well-established logistics and regulatory framework support seamless export operations.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is a prominent pharmaceutical manufacturing zone, offering tax incentives that attract numerous companies. Fresenius Kabi Oncology Limited has a significant presence here, with a state-of-the-art facility dedicated to oncology products. This plant includes dedicated blocks for cytotoxic oral solid dosages and injectable formulations, adhering to stringent international regulatory standards.
5Sourcing Recommendations
- Diversify Supplier Base: While Fresenius Kabi Oncology Limited is the leading exporter, consider engaging with other top suppliers like Eugia Pharma Specialities Limited and Intas Pharmaceuticals Limited to mitigate supply chain risks.
- Leverage Regional Strengths: Utilize the specialized capabilities of different pharmaceutical clusters—Hyderabad for APIs, Ahmedabad-Vadodara for formulations, and Baddi-Nalagarh for cost-effective manufacturing—to optimize sourcing strategies.
- Ensure Regulatory Compliance: Prioritize suppliers with facilities approved by international regulatory authorities such as the USFDA, EMA, and ANVISA to guarantee product quality and compliance.
- Monitor Export Destinations: Align sourcing decisions with key export markets like Germany and the United States to capitalize on established trade routes and demand patterns.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Carboplatin exporters from India
Intas Pharmaceuticals Limited — Intas Pharmaceuticals acquires UDENYCA business from Coherus BioSciences
Intas Pharmaceuticals, through its subsidiary Accord BioPharma, agreed to acquire the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences. UDENYCA is a biosimilar to Neulasta®, used to reduce infection risk in chemotherapy patients. - IMPACT: This acquisition is expected to enhance Intas Pharmaceuticals' biosimilar portfolio, potentially increasing its market share in oncology treatments, including Carboplatin.
Impact: This acquisition is expected to enhance Intas Pharmaceuticals' biosimilar portfolio, potentially increasing its market share in oncology treatments, including Carboplatin.
Common Questions — Carboplatin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which carboplatin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, FRESENIUS KABI ONCOLOGY LIMITED leads with 735 recorded shipments worth $27.5M. EUGIA PHARMA SPECIALITIES LIMITED (66 shipments) and INTAS PHARMACEUTICALS LIMITED (190 shipments) are also established high-volume exporters.
Q How many carboplatin manufacturers are there in India?
India has 273 active carboplatin exporters with a combined export market of $70.9M across 3,637 shipments to 138 countries. The top 5 suppliers hold 65.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for carboplatin from India?
Average FOB unit price: $16.64 per unit, ranging from $0.00 to $2205.87. Average shipment value: $19.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 273 verified Indian exporters of Carboplatin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,637 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 138 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,637 Verified Shipments
273 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists